FDA Seeks End of Road for Compounded Biologics
By Mari Serebrov
Monday, March 25, 2013
If the FDA gets the authority it wants, it could be the end of the road for compounded versions of some biologics and high-risk drugs. In the aftermath of a deadly meningitis outbreak, the agency is working with lawmakers on legislation that would set stricter standards for compounding pharmacies and increase the agency's oversight.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.